The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells.

ABSTRACT:

Background

Hundreds of ongoing clinical trials combine radiation therapy, mostly delivered as stereotactic body radiotherapy (SBRT), with immune checkpoint blockade. However, our understanding of the effect of radiotherapy on the intratumoral immune balance is inadequate, hindering the optimal design of trials that combine radiation therapy with immunotherapy. Our objective was to characterize the intratumoral immune balance of the malignant prostate after SBRT in patients.

Methods

Sixteen patients with high-risk, non-metastatic prostate cancer at comparable Gleason Grade disease underwent radical prostatectomy with (n = 9) or without (n = 7) neoadjuvant SBRT delivered in three fractions of 8 Gy over 5 days completed 2 weeks before surgery. Freshly resected prostate specimen

SUBMITTER: Nickols NG 

PROVIDER: S-EPMC7794088 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature